Updated:
OvaScience
OvaScience is a private life sciences firm in Waltham, Mass., focused on fertility treatments and egg precursor cell technology.
OvaScience
OvaScience is a biotechnology company founded in 2011 in Waltham, Massachusetts. It focuses on developing treatments for infertility, including OvaPrime, OvaTure, and AUGMENT, which is available in Japan through a partnership with IVF Japan. OvaTure and AUGMENT are designed to provide fertility treatment without hormone stimulation.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Sector focus
Frequently asked questions
What happened to OvaScience after its Nasdaq delisting?
OvaScience delisted from Nasdaq in 2017 following product development setbacks and a strategic review. It reorganized as a private entity, but the exact ownership structure and capital sources have not been publicly disclosed.
Does OvaScience manage external capital or function as a family office?
OvaScience does not present itself as a family office or asset manager. It is a private firm operating in the life sciences space, primarily focused on its intellectual property and internal R&D, with no publicly disclosed investment mandate.
What is the science behind OvaScience's fertility treatments?
OvaScience's platform is based on egg precursor cells, also known as oogonial stem cells, which are intended to be harvested and reactivated to improve ovarian function. This approach was developed from animal research and is patented, though it has not achieved commercial success.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: